In the race to make the Corona vaccine, many pharma companies are looking for effective avenues. Johnson & Johnson is testing the company single-shot vaccine, while candidates are traditionally given two shots. At the same time, Bharat Biotech has announced to make the intranasal vaccine, which will differentiate it from intramuscular people.
Nasal vaccine
Most corona vaccines are administered intramuscularly, ie, injected into the muscle. This process requires medical professionals and equipment. Whereas the intranasal vaccine will not have all these requirements and will also cost less.
For this type of vaccine, Bharat Biotech has tied up a license agreement with the Washington University School of Medicine. The company's managing director and chairman Krishna Ella said that we are proud to support this innovative vaccine. We imagine that one billion doses of this vaccine will be produced.
One-shot vaccine
All vaccines being produced by Moderna, Pfizer, and AstraZeneca are double-shot vaccines, given in a patient at intervals of weeks. The intranasal vaccines of Johnson & Johnson and Bharat Biotech will be single-shot vaccines.
Researcher of the J&J Kovid-19 vaccine, Dr. Dan Baruch, says the benefits of the single-shot vaccine are potentially profound in the context of mass vaccination campaigns and global epidemic control. Testing has shown that the Johnson & Johnson company's vaccine is creating strong immunity in patients.
Passive vaccine
Developing a passive vaccine for Kovid-19 is a possibility as scientists have identified highly effective antibodies against the new Coronavirus. In place of active vaccination, passive vaccination involves the administration of antibodies made, which are completed a few days.
Plasma therapy works in such mechanisms. However, scientists are exploring whether it can be used to vaccinate people not yet infected with the corona.